Hot on the heels of the FDA reviewing Sandoz's generic tirzepatide they're also going to review Hybio's application.
I'm super excited that we have generic manufacturers already queuing up to serve this market.
The patent expires in the US in 2036 but they're already moving ahead to get approval to sell the generics in preparation. Excellent.
This is relevant to us in the context of the PBS negotiations. I'd be very curious as to what price has been offered and how that'd go with our value for money formulas for the PBS.
They compared active users to former users to remove the cohort bias of "people that can afford to access GLP-1s".
Correlation is not causation, but it does fit with what we consistently hear in these groups...
>In this cross-sectional study of 821 US adults, who had ever used GLP-1 RA medications, current GLP-1 RA use was associated with significantly weaker associations between impulsivity and violent crime, as well as between alcohol use and violent crime, compared with former use. Interaction terms indicated that the associations of impulsivity and alcohol use with violent behavior were attenuated by approximately 62% and 52%, respectively, among current versus former GLP-1 RA users.
>Sensitivity analyses across diverse GLP-1 RA user groups and comparators provide consistent evidence for an interaction between GLP-1 RA use and impulsivity negatively associated with violence.
I wonder if we'll see crime prescriptions in the future.
I get it, you're in a calorie deficit and it feels harder, but you gotta focus on your overall health. Fold that exercise into your daily routine!
> The Therapeutic Goods Administration has named unapproved peptides as a new priority focus area.
> The regulator warned responses to the importation, supply, manufacturing or advertising of unlawful peptides might include product seizures, infringement notices and even civil or criminal penalties where appropriate.